`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 1 of 35 PagelD# 28825
`
`EXHIBIT L
`EXHIBIT L
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 2 of 35 PageID# 28826
`
`UPDATES FROM FDA’S
`CENTER FOR TOBACCO PRODUCTS
`
`Mitch Zeller, J.D.
`Director, FDA Center for Tobacco Products
`
`Disclaimer: This is not a formal dissemination of information by FDA and does not represent Agency position or policy.
`
`October 27, 2021
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 3 of 35 PageID# 28827
`
`AGENDA
`
`• Programmatic Updates
`- Latest Data on Youth E-Cigarette Use
`- Product Review: Progress on Tobacco Product Application
`Review
`- Compliance and Enforcement
`- Rules and Guidances
`- Public Education Campaigns
`• A New Challenge: Synthetic Nicotine
`• Q&A
`
`1
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 4 of 35 PageID# 28828
`
`LATEST DATA ON YOUTH E-CIGARETTE USE
`
`2
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 5 of 35 PageID# 28829
`
`2021 NATIONAL YOUTH TOBACCO SURVEY FINDINGS
`
`On Oct. 1, FDA and CDC released findings from the 2021 National Youth Tobacco Survey
`(NYTS) on e-cigarette use among middle and high school students
`
`3
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 6 of 35 PageID# 28830
`
`METHODOLOGICAL CHANGES DUE TO COVID-19
`
`• This NYTS—administered Jan. 18 through May 21, 2021—was the first to be fully
`conducted during the COVID-19 pandemic
`
`• Data were collected using an online survey to allow eligible students to participate in the
`classroom, at home, or in some other place to account for various school settings during
`this time
`
`• Different from years before the pandemic, when the survey was conducted exclusively
`in the classroom at school
`
`• Because of the changes in the way the survey was conducted this year, 2021 NYTS
`results cannot be compared to findings from previous surveys
`
`4
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 7 of 35 PageID# 28831
`
`2021 NYTS KEY FINDINGS
`
`5
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 8 of 35 PageID# 28832
`
`FLAVORED ENDS PRODUCTS AND YOUTH USE
`
`• Our concern about youth use of e-cigarettes—especially those the data show are most
`appealing to, and used by, youth—remains high
`
`• We continue to address youth use of e-cigarettes through:
`
`– Premarket review of tobacco product applications
`
`– Compliance and enforcement efforts
`
`– Public education campaigns
`
`6
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 9 of 35 PageID# 28833
`
`PRODUCT REVIEW: PROGRESS ON TOBACCO PRODUCT
`APPLICATION REVIEW
`
`7
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 10 of 35 PageID#
`28834
`
`FDA’S TOBACCO AUTHORITIES
`
`• The Tobacco Control Act—passed in 2009—gave FDA immediate authority to regulate
`cigarettes, smokeless tobacco, cigarette tobacco, and roll-your-own tobacco
`
`• When FDA’s “Deeming Rule” went into effect on Aug. 8, 2016, FDA’s authority expanded
`to cover e-cigarettes and all other electronic nicotine delivery systems (ENDS), cigars, pipe
`tobacco, nicotine gels, and hookah tobacco
`
`• As a result, deemed products are now subject to the same requirements in the Tobacco
`Control Act that apply to cigarettes, smokeless tobacco, cigarette tobacco, and roll-your-
`own tobacco
`
`– This includes the requirement that a new tobacco product must receive premarket
`authorization from FDA to be legally marketed
`
`8
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 11 of 35 PageID#
`28835
`
`PREMARKET APPLICATIONS
`
`• Applications for premarket review for certain deemed new tobacco products on the market
`as of Aug. 8, 2016, were required to be submitted to FDA by Sept. 9, 2020
`
`– Per a court ruling issued Aug. 19, 2020, FDA is not enforcing this requirement for premium cigars
`
`• FDA received applications for more than 6.5 million deemed new tobacco products,
`most of which were submitted very close to the Sept. 9 deadline
`
`• Most applications were premarket tobacco product applications (PMTAs) for ENDS
`products, like e-cigarettes, which had never previously been through the FDA review
`process
`
`9
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 12 of 35 PageID#
`28836
`
`REVIEW OF PMTAS
`
`• FDA’s job is to assess the applicant’s scientific evidence to
`determine if the marketing of the tobacco product is
`“appropriate for the protection of the public health”
`
`• This means we have to assess the risks and benefits to the
`population as a whole, including:
`
`– Users and nonusers of the product under review
`
`– Whether people who currently use any tobacco product would stop
`
`– Whether nonusers would start
`
`10
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 13 of 35 PageID#
`28837
`
`REVIEW PROGRESS
`
`• FDA has taken action on more than 98% of the over 6.5 million products in the timely
`submitted applications. As of Oct. 13, this includes:
`
`– Completing acceptance review for all applications submitted by the Sept. 9 deadline, which
`resulted in issuing refuse to accept (RTA) letters to more than 200,000 applications
`
`– Completing filing review for almost all timely submitted PMTAs, including issuing a refuse to file
`(RTF) letter to a single company for PMTAs associated with approximately 4.5 million products
`
`– Issuing Substantial Equivalence (SE) marketing orders covering more than 120 products
`
`– Issuing Exemption from SE marketing orders covering more than 230 products
`
`– Issuing marketing denial orders (MDOs) for more than 1 million non-tobacco flavored ENDS
`products
`
`– Issuing marketing granted orders for 3 new tobacco products
`
`11
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 14 of 35 PageID#
`28838
`CONSIDERATIONS DURING REVIEW OF NON-TOBACCO
`FLAVORED ENDS PRODUCTS
`
`• Non-tobacco flavored ENDS products pose a known and significant risk with respect to
`youth appeal, uptake, and use
`
`• ENDS continue to be the most used type of tobacco product among youth
`
`– More than 80% of youth who use ENDS report using a flavored product—with fruit being the most
`reported flavor type overall, by school level, and across all e-cigarette devices
`
`– Youth ENDS users are more likely to use flavored ENDS compared with adult END users
`
`– Studies consistently show that flavors influence youth initiation of ENDS use
`
`12
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 15 of 35 PageID#
`28839
`CONSIDERATIONS DURING REVIEW OF NON-TOBACCO
`FLAVORED ENDS PRODUCTS
`
`• Companies who want to continue to market their flavored ENDS
`products must have robust and reliable evidence showing
`that their products’ potential benefit for adult smokers outweighs
`the significant known risk to youth
`
`• By contrast, tobacco-flavored ENDS raise a different set of
`considerations because they do not pose the same degree of
`risk of youth uptake
`
`13
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 16 of 35 PageID#
`28840
`AUTHORIZATION OF ENDS PRODUCTS THROUGH THE
`PMTA PATHWAY
`
`• On Oct. 12, FDA authorized the marketing of three new tobacco products, marking
`the first set of ENDS products ever to be authorized by FDA
`
`• R.J. Reynolds (RJR) Vapor Company submitted data that demonstrates its tobacco-
`flavored products could benefit addicted adult smokers who switch to these products—
`either completely or with a significant reduction in cigarette consumption—by reducing
`their exposure to harmful chemicals
`
`• Additionally, FDA considered the risks and benefits to the population as a whole and
`determined the potential benefits to smokers outweigh the risk to youth
`
`• FDA also issued 10 MDOs for RJR’s flavored Vuse Solo ENDS products
`
`14
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 17 of 35 PageID#
`28841
`PMTA AUTHORIZATION: NEW ORAL TOBACCO PRODUCTS
`
`• On Oct. 19, FDA authorized the marketing of four oral tobacco products
`manufactured by U.S. Smokeless Tobacco Company LLC (USSTC) under the brand name
`of VERVE®
`
`• These are mint flavored products, containing nicotine, that are chewed and then discarded
`when the user is finished
`
`• The company submitted data that demonstrates these products could benefit addicted
`adult smokers who switch to them—either completely or with a significant reduction in
`cigarette consumption—by reducing their exposure to harmful chemicals
`
`• Additionally, research shows a low likelihood that youth, non-smokers, or former
`smokers would initiate or reinitiate tobacco use with these products
`
`15
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 18 of 35 PageID#
`28842
`REMAINING PENDING APPLICATIONS
`
`• FDA continues to work expeditiously on the remaining applications that were submitted by
`the court’s Sept. 9, 2020, deadline, many of which are in the final stages of review
`
`– The agency has around 80,000 products pending that are the subject of timely submitted
`PMTAs
`
`• FDA continues to review PMTAs for non-tobacco flavored ENDS to determine whether
`there is sufficient product-specific scientific evidence of a benefit to adult smokers to
`overcome the risk posed to youth
`
`– The scientific review of menthol ENDS raises unique considerations, and FDA is reviewing
`every product on a case-by-case basis with the same review standards
`
`• FDA is also reviewing a smaller number of pending applications under the SE
`standard for cigars, pipes, and hookah tobacco
`
`16
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 19 of 35 PageID#
`28843
`LEGAL CHALLENGES AND APPEALS
`
`• As of Oct. 26, 46 cases filed for judicial review of specific MDO actions (45 pending)
`
`• Dozens of requests for supervisory review of negative actions (under Title 21 of Code of
`Federal Regulations section 10.75)
`
`17
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 20 of 35 PageID#
`28844
`
`COMPLIANCE AND ENFORCEMENT
`
`18
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 21 of 35 PageID#
`28845
`FDA’S ENFORCEMENT PRIORITIES
`
`• All new tobacco products on the market without the statutorily required premarket
`authorization are marketed unlawfully and are subject to enforcement action at FDA’s
`discretion
`
`• As described in FDA’s enforcement guidance, we have identified flavored products that
`appeal to youth as enforcement priorities
`
`• Products for which no application is pending, including, for example, those with an
`MDO and those for which no application was submitted, are among our highest
`enforcement priorities
`
`19
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 22 of 35 PageID#
`28846
`UPDATE ON COMPLIANCE AND ENFORCEMENT
`
`• FDA has been closely monitoring manufacturer, importer, and distributor
`compliance with the premarket authorization requirement
`
`• Since Jan. 2021, FDA has issued 173 warning letters to firms that
`collectively have listed more than 17 million ENDS products with FDA
`and did not submit premarket applications for these products
`
`• On Oct. 7, FDA issued warning letters to 22 companies for unlawfully
`marketing products that are subject to MDOs and/or RTF determinations
`on their premarket applications
`
`20
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 23 of 35 PageID#
`28847
`
`RULES AND GUIDANCES
`
`21
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 24 of 35 PageID#
`28848
`
`PMTA AND SE FINAL RULES
`
`• On Oct. 5, FDA published two final rules in the
`Federal Register for the premarket review of new
`tobacco products—and they are effective Nov. 4
`
`• These foundational rules provide additional information
`on the requirements for the content, format, and
`review of Premarket Tobacco Product Applications
`(PMTAs) and Substantial Equivalence (SE) Reports
`
`• Finalizing these rules helps ensure all future PMTAs and
`SE Reports contain the basic information FDA needs
`to determine whether the new tobacco products meet
`the relevant premarket requirements to efficiently and
`effectively implement the Tobacco Control Act
`
`22
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 25 of 35 PageID#
`28849
`LOOKING AHEAD: PROPOSED PRODUCT STANDARDS
`
`•
`
`In April, FDA announced it is working toward issuing proposed
`product standards in Spring 2022. FDA plans to:
`– ban menthol as a characterizing flavor in cigarettes
`– ban all characterizing flavors in cigars
`• This decision is based on clear science and evidence
`establishing the addictiveness and harm of these products
`and builds on important, previous actions that banned other
`flavored cigarettes in 2009
`
`• These actions will help significantly reduce youth initiation,
`increase the chances of smoking cessation among current
`smokers, and address health disparities experienced by
`communities of color, low-income populations, and LGBTQ+
`individuals
`
`23
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 26 of 35 PageID#
`28850
`
`PUBLIC EDUCATION CAMPAIGNS
`
`2424
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`
`
`CENTER FOR TOBACCO PRODUCTSCENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 27 of 35 PageID#
`28851
`“THE REAL COST” YOUTH E-CIGARETTE USE PREVENTION
`CAMPAIGN
`
`• Since 2017, FDA’s award-winning public education
`campaign “The Real Cost” has been prioritizing e-
`cigarette prevention messaging to address alarming
`youth vaping rates
`
`•
`
`“The Real Cost” Youth E-Cigarette Prevention Campaign
`reaches youth aged 12 to 17 who have used e-
`cigarettes or are open to trying them
`
`• Campaign messages focus on educating youth that
`using e-cigarettes, just like cigarettes, puts them at risk
`for addiction and other health consequences
`
`25
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 28 of 35 PageID#
`28852
`
`CAMPAIGN REACH
`
`• Since “The Real Cost” E-Cigarette Prevention effort launched, the campaign has shown
`effective reach and engagement results—reaching up to 85% of all teens nationwide
`through paid media messages
`
`• Across social media, FDA has engaged teen audiences with more than 3.9 million likes,
`more than 355,000 shares, and more than 90,000 comments—with 10% of comments
`coming from teens asking for help and resources to quit vaping
`
`• FDA also collaborated with the National Cancer Institute to develop vaping cessation
`content for teens on Teen.SmokeFree.gov
`
`– Since the content launched in 2019, there have been more than 2 million page views
`
`– Visitors spend an average of 4 minutes per page to learn how to quit vaping, manage nicotine
`withdrawal, and deal with stress and anxiety
`
`26
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 29 of 35 PageID#
`28853
`
`A NEW CHALLENGE: SYNTHETIC NICOTINE
`
`27
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 30 of 35 PageID#
`28854
`A RISE IN SYNTHETIC NICOTINE
`
`•
`
`Increasing number of ENDS products that use, or
`claim to use, synthetic nicotine instead of
`nicotine derived from tobacco
`
`– Includes Puff Bar, reported in the 2021 NYTS as the
`most popular brand among youth e-cigarette users
`
`• To try to avoid FDA regulation and evade
`enforcement, several companies that received
`MDOs are publicly saying they are switching to
`synthetic nicotine to keep their products on the
`market
`
`“
`
`VaporSalon is switching to
`TOBACCO FREE NICOTINE on
`Friday, 8/27/2021. … F*** the
`FDA and their over-reaching
`over-burdensome regulations
`that small businesses were never
`ever going to be successful in
`completing and they knew that
`from the start.
`
`”
`
`28
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 31 of 35 PageID#
`28855
`KEY CHALLENGES WITH SYNTHETIC NICOTINE
`
`• The definition of “tobacco product” includes any product made or derived from
`tobacco, including a component, part, or accessory of a tobacco product
`
`• E-liquids that do not contain nicotine or other substances made or derived from tobacco
`may still be components or parts of tobacco products and, therefore, subject to
`FDA's tobacco control authorities
`
`• FDA intends to make these determinations on a case-by-case basis, based on the totality
`of the circumstances
`
`29
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 32 of 35 PageID#
`28856
`KEY CHALLENGES WITH SYNTHETIC NICOTINE
`
`•
`
`It’s becoming more difficult to test and differentiate tobacco-derived nicotine from
`synthetic nicotine
`
`• Nicotine has two isomer forms (R- and S-nicotine)
`
`– Tobacco-derived nicotine is 99% S-nicotine
`
`– Previous synthetic nicotine formulations were 50/50 nicotine isomers
`
`– Newer synthetic nicotine formulations can consist of more than 99% S-nicotine
`
`• Tobacco-derived nicotine is now readily available as higher quality U.S. pharmaceutical-
`grade 99% nicotine, which no longer contains traditional tobacco agricultural markers
`like tobacco DNA or tobacco specific nitrosamines – making it harder to distinguish
`tobacco-derived nicotine from synthetic
`
`30
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 33 of 35 PageID#
`28857
`FDA’S REGULATORY PATH FORWARD
`
`• FDA is very concerned about the implications of companies
`attempting to evade regulation by using synthetic nicotine,
`particularly as it regards to potential youth ENDS use
`
`•
`
`In the short term, the agency is exploring how to best address the
`growing number of products where the jurisdiction is under
`review due to the source of nicotine
`
`• FDA is also in discussions with Congress about a potential
`legislative fix
`
`31
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 34 of 35 PageID#
`28858
`ADDITIONAL FDA PRESENTATION
`
`Matthew R. Holman, Ph.D., Director,
`
`Office of Science, Center for Tobacco Products
`
`1:30 – 2:40 p.m.
`
`- Panel coming up next after the break -
`
`Pre-Market Tobacco Applications (PMTAs):
`
`Recent Decisions and Surveying the Post-Deadline Landscape
`
`32
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 1017-12 Filed 02/11/22 Page 35 of 35 PageID#
`28859
`CONTACTING/FOLLOWING FDA’S CENTER FOR TOBACCO
`PRODUCTS
`
`• Report adverse experiences with tobacco products at:
`https://www.safetyreporting.hhs.gov
`
`• Call us: (877) CTP-1373
`
`• Email us: AskCTP@fda.hhs.gov
`
`• Follow us on Twitter: @FDATOBACCO
`
`33
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`